dc.contributor
Institut Català de la Salut
dc.contributor
[Banerjee S] Gynaecology Unit, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, UK. [Gonzalez-Martin A] Gynaecology Unit, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, UK. [Harter P] Department of Gynaecology and Gynaecological Oncology, Ev. Kliniken Essen-Mitte, Essen, Germany. [Lorusso D] Scientific Directorate and Gynecologic Oncology Unit, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy. [Moore KN] Stephenson Cancer Center, University of Oklahoma, Norman, Oklahoma, USA. [Oaknin A] Servei d’Oncologia Mèdica, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Gonzalez-Martin, Antonio
dc.contributor.author
Harter, Philipp
dc.contributor.author
Lorusso, Domenica
dc.contributor.author
Moore, Kathleen N
dc.contributor.author
Oaknin Benzaquen, Ana Mazaltob
dc.contributor.author
Banerjee, Susana
dc.date.accessioned
2025-10-25T05:37:27Z
dc.date.available
2025-10-25T05:37:27Z
dc.date.issued
2021-09-20T10:03:20Z
dc.date.issued
2021-09-20T10:03:20Z
dc.date.issued
2020-12-11
dc.identifier
Banerjee S, Gonzalez-Martin A, Harter P, Lorusso D, Moore KN, Oaknin A, et al. First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open - Cancer Horizons round-table discussion. ESMO Open. 2020 Dec 11;5:e001110.
dc.identifier
https://hdl.handle.net/11351/6331
dc.identifier
10.1136/esmoopen-2020-001110
dc.identifier
000608044000001
dc.identifier.uri
http://hdl.handle.net/11351/6331
dc.description.abstract
Inhibidors de PARP; Càncer d’ovari avançat
dc.description.abstract
Inhibidores de PARP; Cáncer de ovario avanzado
dc.description.abstract
PARP inhibitors; Advanced ovarian cancer
dc.description.abstract
Poly(ADP-ribose) polymerase (PARP) inhibitor maintenance therapy is the latest breakthrough in the management of newly diagnosed advanced ovarian cancer. The results of the SOLO-1 trial in 2018 led to European Medicines Agency and Food and Drug Administration approval of olaparib as first-line maintenance therapy in patients with BRCA1/2 mutation, establishing a new standard of care. Subsequently, the results of three phase III trials (PRIMA, PAOLA-1, VELIA) evaluating the use of first-line PARP inhibitors beyond patients with BRCA1/2 mutations and as combination strategies were presented in 2019, leading to the recent approval of maintenance niraparib irrespective of biomarker status and olaparib in combination with bevacizumab in homologous recombination deficiency-positive-associated advanced ovarian cancer. An ESMO Open - Cancer Horizons round-table expert panel discussed the four phase III trials of first-line PARP inhibitor therapy and how they are changing the clinical management of advanced ovarian cancer.
dc.description.abstract
The project is supported by an unrestricted educational grant from AstraZeneca. The authors received an honorarium for their participation in the round table from BMJ.
dc.format
application/pdf
dc.relation
https://doi.org/10.1136/esmoopen-2020-001110
dc.rights
Attribution-NonCommercial 4.0 International
dc.rights
http://creativecommons.org/licenses/by-nc/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Ovaris - Càncer -Tractament
dc.subject
Inhibidors enzimàtics - Ús terapèutic
dc.subject
DISEASES::Neoplasms::Neoplasms by Site::Endocrine Gland Neoplasms::Ovarian Neoplasms
dc.subject
CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors::Poly(ADP-ribose) Polymerase Inhibitors
dc.subject
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de las glándulas endocrinas::neoplasias ováricas
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::mecanismos moleculares de acción farmacológica::inhibidores enzimáticos::inhibidores de poli(ADP-ribosa) polimerasas
dc.title
First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open - Cancer Horizons round-table discussion
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
